François-Clément Bidard
Institut Curie (France) · Institut Curie · INSTITUT CURIE - Medical Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name François-Clément Bidard as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:59 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07717450 · Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.UNICANCER · not yet recruiting · Metastatic Invasive Breast Cancer · study chair
- Ph3NCT07237256 · Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibUNICANCER · recruiting · Breast Cancer · principal investigator
- Ph2NCT07193394 · Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerInstitut Curie · recruiting · Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer · principal investigator
- N/ANCT06225505 · Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)Institut Curie · recruiting · Triple Negative Breast Cancer · principal investigator
- Ph2NCT06175390 · Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast CancerInstitut Curie · active not recruiting · Triple Negative Breast Cancer · principal investigator
- Ph2NCT05955170 · Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerInstitut Curie · recruiting · HER2-positive Breast Cancer · principal investigator
- Ph2NCT05932667 · Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast CancerInstitut Curie · terminated · Advanced or Metastatic Breast Cancer · principal investigator
- Ph2NCT04720729 · Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast CancerInstitut Curie · terminated · HER2-negative Metastatic Breast Cancer · study director
- N/ANCT04367870 · COVID-19 Detection Test in OncologyUNICANCER · completed · Oncology · principal investigator
- N/ANCT03739775 · Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)Institut Curie · completed · HPV Positive Pelvic Cancer · principal investigator
- Ph3NCT03079011 · PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionUNICANCER · completed · Metastatic Breast Cancer · principal investigator
- N/ANCT02866149 · Analysis of Circulating Tumor Markers in the Blood (ALCINA)Institut Curie · completed · Cancer · study director
- N/ANCT02860481 · FSH-R : Diagnostic Application for Localized Tumors in CancerologyInstitut Curie · terminated · Cancer
- N/ANCT02220556 · Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral PathologyInstitut Curie · completed · Solid Tumor, Adult · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:59 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- 670 citationsRCR 45.8
- 327 citationsRCR 20.7
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Ann Oncol · 2014302 citationsRCR 7.5
- 231 citationsRCR 7.1
- 225 citationsRCR 5.8
- Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.Ann Oncol · 2010195 citationsRCR 4.5
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.N Engl J Med · 2025189 citationsRCR 43.2
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.N Engl J Med · 2025177 citationsRCR 36.0
- Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.Ann Oncol · 2013164 citationsRCR 4.7
- 147 citationsRCR 7.6